“Do the savings at Costco justify the price of driving out there? Or should I pay more at one of the grocery stores within walking distance?” DAKOTA WYLDE, who lost his job as a contractor at the ...

Sam Altman, OpenAI’s CEO and the public face of ChatGPT, has carved out an image for himself as one of the preeminent AI whisperers of our age, whose influence supposedly extends to the White House on ...

Coders have had a field day weeding through the treasures in the Claude Code leak. "It has turned into a massive sharing party," said Sigrid Jin, who created the Python edition, Claw Code. Here's how ...

The publisher filed a lawsuit in Munich last week, accusing OpenAI of violating copyright laws after ChatGPT allegedly copied a popular German book series, according to The Guardian: In response to ...

The Python team at Microsoft is continuing its overhaul of environment management in Visual Studio Code, with the August 2025 release advancing the controlled rollout of the new Python Environments ...

Claude Code users have been flooding GitHub and Reddit over the last few days with complaints that their usage limits are being exhausted at a suspiciously fast rate, with many reporting that sessions ...

Last week, cybersecurity researchers uncovered a hacking campaign targeting iPhone users that used an advanced hacking tool called DarkSword. Now someone has leaked a newer version of DarkSword and ...

OpenAI is developing a "super app" for desktop that unifies ChatGPT, its browser and its Codex app, according to the Wall Street Journal and CNBC. A company spokesperson told the publications that ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

The radio signal first started broadcasting on February 28, about 12 hours after the United States and Israel began bombing Iran. On a scratchy shortwave signal almost twice a day -- in the early ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...